Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage.

Cardiovasc Diabetol · 2026 · PMC13401296 · PMID 42498959

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In our analysis we detected a highly significant reduction of ac4C in plasma in patients treated with dapagliflozin or empagliflozin.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.